



Drug Monograph

Drug/Drug **Lonhala Magnair[®] (glycopyrrolate) solution /COPD**

Class:

Prepared for: MO HealthNet

Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Lonhala Magnair [®] is available in a starter kit containing 60 unit-dose vials packaged with one Magnair nebulizer system. It is also available in a refill kit containing 60 unit-dose vials packaged with a Magnair replacement handset.
Manufacturer:	Sunovion Respiratory Development Inc., Marlborough, MA 01752.
Indications:	Lonhala Magnair [®] is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
Costs:	\$1,132.80 per kit of Lonhala Magnair [®] . Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Non-Preferred <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer PharmD

Date: May 18, 2018